Profile avatar
rnflex.bsky.social
Jack of all trades nurse practitioner, trail runner photographer, coonhound rescuer, lover of glucagon agonism in the liver, kidney and pancreas, fascinated by obesity medicine, retatrutide fan boy
2,808 posts 2,286 followers 376 following
Regular Contributor
Active Commenter
Posts 14 Comments 36

This may end up as a long form post, but I have a hypothesis as to why glucagon agonist work so well for weight loss and potentially the mechanism for increased energy expenditure. Futile cycling of substrates. Specifically lipids(and to a lesser extent glucose) Here's my rationale, in a short🧵

submitted 1 hour ago • 1 comment

With the American Diabetes Association Scientific conference right around the corner, expect to hear A LOT of news surrounding Amylin agonists. They may be another effective method for weight loss independently of GLP-1

submitted 1 day ago • 0 comments

Mazdutide, via its dual GLP-1/GCGR activation effects, exerts multifactorial neuroprotective-related improvements in cognitive function in male db/db mice id.elsevier.com/as/authoriza...

submitted 2 days ago • 0 comments

Part 2 published! Last week was glucagon antagonists, this week, glucagon agonists. They're coming in 2026 and they're about to make Ozempic obsolete. Read on and find out why glucagon, once shunned by medicine is about to have its moment in the spotlight

submitted 4 days ago • 1 comment

Apparently I'm the 1% that tries to screen a UACR on my chronic hypertension patients once a year and absolutely for a new diagnosis of HTN. Yikes. We need to do a lot better

submitted 3 days ago • 0 comments

Part 2 published! Last week was glucagon antagonists, this week, glucagon agonists. They're coming in 2026 and they're about to make Ozempic obsolete. Read on and find out why glucagon, once shunned by medicine is about to have its moment in the spotlight

submitted 4 days ago • 1 comment

New over 22 weeks dapagliflozin, as an adjunct to insulin, in youth with #T1D reduced measured eGFR (mGFR) improved glycemic control and was safe when combined with ketone testing and risk mitigation strategies @uhnresearch.ca @naturemedicine.bsky.social www.nature.com/articles/s41...

submitted 4 days ago • 0 comments

As they continue to fight online, I will just enjoy my flat iron steak, seared hard in a cast iron skillet to a perfect medium rare. Anyways. Good evening.

submitted 5 days ago • 1 comment

LATEST: A conservative culture cost Novo Nordisk its lead in the obesity drug race, former employees told me It wanted to tread carefully as the first mover in the space, and its belief in Ozempic/Wegovy blinded it to other candidates, they said

submitted 5 days ago • 2 comments

Just doing some light reading/research on glucagon today and stumbled upon this which CONFIRMS findings from 2024/25 that glucagon seems to have an inhibitory effect on tumor growth. This paper was published in NINETEEN FIFTY NINE.

submitted 5 days ago • 0 comments

The first #ERA25 simultaneous pub CONFIDENCE trial of empagliflozin + finerenone in N = 579 Greater reduction in ACR and BP Note the impressive GFR dip www.nejm.org/doi/full/10....

submitted 5 days ago • 4 comments

This begs a question. Is Detroit style pizza deep dish? I'd argue no, as it's still only slightly thicker than normal pizza and it's definitely not a casserole

submitted 6 days ago • 1 comment

Dosing tirzepatide or retatrutide once monthly would be kinda awesome for patients that have reached a maintenance state and tolerate the meds well.

submitted 6 days ago • 0 comments

As I write up part 2 of my post on glucagon and why we should agonize it, I'm struck by just how much *OLD* data is out there. We knew glucagon did so much more than raise blood sugar but no one chased it down. Instead it feels like this knowledge was lost to time. I'll be citing a paper from 1960!!

submitted 8 days ago • 1 comment